Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
ARGAN INC director Lisa Larroque Alexander reported routine equity compensation activity. On April 16, 2026, 695 Time-Based Restricted Stock Units vested and were converted into 695 shares of common stock, consistent with a one-year vesting schedule for TRSUs granted on April 16, 2025.
Following these transactions, she directly holds 700 shares of common stock and 530 Time-Based Restricted Stock Units. These entries reflect compensation-related derivative exercises rather than open-market buying or selling.
ARGAN INC director William F. Leimkuhler reported an open-market sale of company shares. On April 13, 2026, he sold 8,444 shares of Common Stock at an average price of $598.49 per share. After this transaction, he directly owns 41,495 shares of ARGAN INC common stock.
Leimkuhler William F. submitted a Form 144 notice relating to proposed sales of Common stock of Argan Inc. The filing lists securities tied to a stock option exercise of 5,852 shares (06/14/2024) and a stock award of 2,592 shares (12/14/2024). The filing also discloses securities sold in the past three months: 4,212 shares sold on 01/13/2026 for $1,350,048.01 and 11,044 shares sold on 01/16/2026 for $4,187,262.86.
Argan Inc. granted equity awards to Charles Edwin Collins IV, Chief Executive Officer of Gemma. On April 8, 2026, he received 10-year options for 332 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting April 8, 2027.
He was also granted 231 time-based RSUs that vest in three equal annual installments from April 8, 2027. In addition, he received performance-based RSUs with a target of 170 shares tied to three-year relative total stock return versus 12 peers, and EPS-based RSUs with a target of 2,618 shares tied to compounded EPS growth over fiscal 2027–2029.
ARGAN INC President and CEO David Hibbert Watson reported new equity awards made on April 8, 2026. He received 10-year options to purchase 415 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting April 8, 2027.
He was also granted 251 time-based RSUs vesting in three equal annual installments from April 8, 2027, 284 performance-based RSUs tied to three-year total shareholder return versus 12 peers, and 3,339 EPS performance-based RSUs with payouts from 0% to 200% based on multi-year earnings targets.
ARGAN INC director William F. Griffin Jr, non-executive chairman of Gemma, received a grant of 3,339 Earnings Per Share Performance-Based Restricted Stock Units on April 8, 2026. These units convert into common stock only if multi-year earnings targets are met.
The vesting depends on the sum of earnings per share for fiscal years ending January 31, 2027, 2028 and 2029, compared with target compounded EPS growth based on fiscal years ended January 31, 2024, 2025 and 2026. The eventual payout can range from 0% to 200% of the 3,339-unit target, aligning compensation with long-term EPS performance.
Argan Inc. Chief Financial Officer Joshua Scott Baugher reported receiving multiple equity awards that increase his potential ownership in the company. On April 8, 2026, he was granted a 10-year option to purchase 208 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting on April 8, 2027.
He was also granted 126 time-based restricted stock units that vest in three equal annual installments beginning April 8, 2027. In addition, he received performance-based restricted stock units targeting 142 shares tied to three-year total shareholder return versus 12 peer companies, and a prior grant of earnings-per-share performance-based units targeting 1,670 shares, both with payout ranges from 0% to 200% of target based on performance over their respective three-year periods.